Bringing new drugs to untreatable diseases

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.   

In this latest episode, DDW’s Megan Thomas is in conversation with Dr Simon Fricker, who just last year was made Chief Development Officer of PepperBio to support the company’s next phase of growth and guide the strategic expansion of Pepper’s oncology pipeline.

Over the course of his career, including eight years as a distinguished scientific fellow at Genzyme/Sanofi, Dr Fricker worked on three approved drugs: Paraplatin, Fosrenol, and Mozobil. Dr. Fricker was a founder of Canadian biopharma company AnorMED, acquired by Genzyme, and awarded the Queen’s Award for Technology for his participation in the development of the anticancer drug Paraplatin.

You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free